Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. / Regeur, L; Colding, H; Jensen, H; Kampmann, J P.

In: Antimicrobial Agents and Chemotherapy, Vol. 11, No. 2, 1977, p. 214-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Regeur, L, Colding, H, Jensen, H & Kampmann, JP 1977, 'Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.', Antimicrobial Agents and Chemotherapy, vol. 11, no. 2, pp. 214-8.

APA

Regeur, L., Colding, H., Jensen, H., & Kampmann, J. P. (1977). Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy, 11(2), 214-8.

Vancouver

Regeur L, Colding H, Jensen H, Kampmann JP. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy. 1977;11(2):214-8.

Author

Regeur, L ; Colding, H ; Jensen, H ; Kampmann, J P. / Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. In: Antimicrobial Agents and Chemotherapy. 1977 ; Vol. 11, No. 2. pp. 214-8.

Bibtex

@article{9c41e4a0b55311ddb04f000ea68e967b,
title = "Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.",
abstract = "The pharmacokinetics of amikacin were examined in six bilaterally nephrectomized patients undergoing hemodialysis and in four patients with a minimal residual renal function undergoing peritoneal dialysis. The mean elimination half-life before the dialysis was 86.5 h in the anephric patients and 44.3 h in the patients with minimal residual kidney function. The results from the anephric patients suggest that some extrarenal elimination of amikacin may occur. The mean volume of distribution was about 25% of the total body weight. This is in accordance with values reported from subjects with normal renal function. During hemodialysis the half-life decreased to less than 10% (5.6 h) of the pretreatment value. The effectiveness of peritoneal dialysis was less as the half-life decreased to only about 30% (17.9 h) of the pretreatment value. During the dialyses a significant correlation between the half-life of amikacin and the decrease in blood urea and serum creatinine was demonstrated. The pharmacokinetic data were used to make dosage regimen recommendations for the treatment of patients undergoing intermittent hemodialysis or peritoneal dialysis.",
author = "L Regeur and H Colding and H Jensen and Kampmann, {J P}",
note = "Keywords: Adult; Amikacin; Female; Half-Life; Humans; Kanamycin; Kinetics; Male; Middle Aged; Peritoneal Dialysis; Renal Dialysis",
year = "1977",
language = "English",
volume = "11",
pages = "214--8",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.

AU - Regeur, L

AU - Colding, H

AU - Jensen, H

AU - Kampmann, J P

N1 - Keywords: Adult; Amikacin; Female; Half-Life; Humans; Kanamycin; Kinetics; Male; Middle Aged; Peritoneal Dialysis; Renal Dialysis

PY - 1977

Y1 - 1977

N2 - The pharmacokinetics of amikacin were examined in six bilaterally nephrectomized patients undergoing hemodialysis and in four patients with a minimal residual renal function undergoing peritoneal dialysis. The mean elimination half-life before the dialysis was 86.5 h in the anephric patients and 44.3 h in the patients with minimal residual kidney function. The results from the anephric patients suggest that some extrarenal elimination of amikacin may occur. The mean volume of distribution was about 25% of the total body weight. This is in accordance with values reported from subjects with normal renal function. During hemodialysis the half-life decreased to less than 10% (5.6 h) of the pretreatment value. The effectiveness of peritoneal dialysis was less as the half-life decreased to only about 30% (17.9 h) of the pretreatment value. During the dialyses a significant correlation between the half-life of amikacin and the decrease in blood urea and serum creatinine was demonstrated. The pharmacokinetic data were used to make dosage regimen recommendations for the treatment of patients undergoing intermittent hemodialysis or peritoneal dialysis.

AB - The pharmacokinetics of amikacin were examined in six bilaterally nephrectomized patients undergoing hemodialysis and in four patients with a minimal residual renal function undergoing peritoneal dialysis. The mean elimination half-life before the dialysis was 86.5 h in the anephric patients and 44.3 h in the patients with minimal residual kidney function. The results from the anephric patients suggest that some extrarenal elimination of amikacin may occur. The mean volume of distribution was about 25% of the total body weight. This is in accordance with values reported from subjects with normal renal function. During hemodialysis the half-life decreased to less than 10% (5.6 h) of the pretreatment value. The effectiveness of peritoneal dialysis was less as the half-life decreased to only about 30% (17.9 h) of the pretreatment value. During the dialyses a significant correlation between the half-life of amikacin and the decrease in blood urea and serum creatinine was demonstrated. The pharmacokinetic data were used to make dosage regimen recommendations for the treatment of patients undergoing intermittent hemodialysis or peritoneal dialysis.

M3 - Journal article

C2 - 848923

VL - 11

SP - 214

EP - 218

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -

ID: 8670279